NCT06025045 is a clinical trial in Ovarian Cancer Stage IV, sponsored by Jing Li.

Who is sponsoring NCT06025045?

NCT06025045 is sponsored by Jing Li.

What condition does NCT06025045 study?

NCT06025045 studies Ovarian Cancer Stage IV, Ovarian Cancer Stage III.

Is NCT06025045 still recruiting?

NCT06025045 is currently status unknown. Last updated 6 September 2023.

Last reviewed 2023-09-06 · How we verify

NCT06025045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Status unknown Last updated 6 September 2023

What this trial tests

trial in Ovarian Cancer Stage IV in 50 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
1 August 2025

1 August 2025

Quick facts

Lead sponsor	Jing Li
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 August 2022
Primary completion	1 August 2025
Estimated completion	1 August 2025
Sites	1 location across China

Conditions studied

Ovarian Cancer Stage IV — all drugs for Ovarian Cancer Stage IV →
Ovarian Cancer Stage III — all drugs for Ovarian Cancer Stage III →

Sponsor

Jing Li — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer Stage IV or Ovarian Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients who receive satisfactory PDS, currently the change in CA125 during chemotherapy can only be used to evaluate the effectiveness of chemotherapy. This study plans to use ctDNA dynamic monitoring to detect minimal residual lesions during treatment, to demonstrate the application value of ctDNA dynamic monitoring in predicting the recurrence of ovarian cancer after PDS/IDS surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ovarian Cancer Stage IV

Currently open trials in the same condition.

NCT07067255 — Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer · Phase 1, PHASE2 · recruiting
NCT06290193 — Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery · Phase 2 · recruiting
NCT06017557 — Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer · NA · recruiting
NCT04701645 — Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer · Phase 1 · recruiting
NCT04997096 — Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera · NA · recruiting

Other Jing Li trials

Trials by the same sponsor.

NCT03177408 — Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06025045 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jing Li
Last refreshed: 6 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06025045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing